Pain at the end stage of cancer is a severe problem for patients. Although non-opioid analgesics are used for patients with mild-to-moderate cancer pain, morphine is the mainstay of the management of pains of patients with terminal cancer.
These findings suggest that pain at the late-phase of this model is similar to the moderate-to-severe pain of cancer patients.
Melanoma-bearing mice show aversive responses to innocuous tactile stimulation (tactile allodynia) and increased aversive responses to noxious mechanical stimulation (mechano-hyperalgesia) at the late phase.
3) Severe tactile allodynia and mechano-hyperalgesia obstruct the daily life and decrease the quality of life of patients. Therefore, in the present experiments, we investigated whether several non-opioid agents which had been shown to inhibit neuropathic or inflammatory pain would inhibit the tactile allodynia and mechano-hyperalgesia of melanoma-bearing mice. Animals Male C57BL/6 mice (6 weeks of age at the melanoma inoculation; Japan SLC Ltd., Shizuoka) were used. They were kept in a room under controlled temperature (22Ϯ1°C), humidity (55Ϯ10%) and light (lights on 0700-1900 h). Food and water were available ad libitum. The study was approved by the Committee for Animal Experiments at Toyama Medical and Pharmaceutical University.
MATERIALS AND METHODS

Materials
Tumor Inoculation B16-BL6 cells (2ϫ10 5 cells), melanoma derived from melanocyte of the C57BL/6 mouse, were inoculated into the plantar region of unilateral hind paw.
2)
Behavioral Test Von Frey filaments with a bending force of 0.07 or 1.2 g were pressed against the plantar skin with it slightly buckled and responses were scored as follows: 0ϭno response; 1ϭmoving away from the filament; 2ϭimmediate flinching or licking of the hind paw. 4, 5) The stimulation of the same intensity was applied six times to each test site at intervals of several seconds and the average served as pain-related score. After melanoma growth, the periphery of tumor mass was stimulated with the filaments.
3)
Statistical Analysis Data were presented as the meanϮ S.E.M. Results were analyzed with Mann-Whitney U-test or Kruskal-Wallis analysis of variance on ranks and post hoc Dunnett's test; pϽ0.05 was considered significant.
RESULTS
Tactile allodynia (response to the filament of 0.07 g strength) and mechano-hyperalgesia (response to the filament of 1.2 g strength) abruptly increased in the tumor region on days 11-14 post-inoculation and thereafter relatively con- (Fig. 1) . It also inhibited the response of the contralateral hind paw to the filament of 1.2 g strength 3 h after injection (Fig. 1 ). The lower dose of 100 mg/kg produced partial and slight inhibition of allodynia and hyperalgesia, respectively, without effects on the contralateral hind paw (Fig. 1) . In another series of experiments, gabapentin (150 mg/kg, p.o.) produced the almost complete inhibition of allodynia and hyperalgesia, without effects on the contralateral paw, the time courses of which were similar to those of a dose of 300 mg/kg (nϭ7; data not shown). Ketamine hydrochloride (30 mg/kg, i.p.) partially inhibited allodynia 15 min after injection; pain-related scores were 1.83Ϯ0.11, 0.60Ϯ0.23 and 1.67Ϯ0.14 (nϭ6) before, 15 min and 30 min after injection. It did not affect the response to the filament of 1.2 g strength, but mice showed slight prostrate posture 15 min after injection. Diclofenac sodium (10 and 30 mg/kg, i.p.; nϭ4), mexiletine hydrochloride (20 mg/kg, i.p.; nϭ6), clonidine hydrochloride (0.1 mg/kg, i.p.; nϭ6), suramin (100 mg/kg, i.p.; nϭ4), baclofen (3 mg/kg, s.c., nϭ 4) and N G -nitro-L-arginine methyl ester (100 mg/kg, s.c.; nϭ 6) did not affect the allodynia and hyperalgesia (data not shown).
Suppression by Gabapentin of Pain-Related Mechano-Responses in Mice Given Orthotopic Tumor Inoculation
Repeated administration of gabapentin (150 mg/kg, p.o., once a day from day 14 post-inoculation) produced the constant inhibition of allodynia and hyperalgesia for 7 d (Fig. 2) .
DISCUSSION
Among seven agents examined, only gabapentin (100-300 mg/kg) suppressed allodynia and hyperalgesia without effects on gross behaviors. The effective doses (Ն100 mg/kg) were higher than those which inhibit allodynia and hyperalgesia in rodents with neuropathic pain, in which minimum effective dose was 10-30 mg/kg. [6] [7] [8] Mice appeared to be sedative after the highest dose (300 mg/kg) tested, but the same dose does not affect spontaneous locomotor activity in mice. 9) Therefore, the inhibition of pain-related responses may not be due to the suppression of locomotor activity. In human subjects, gabapentin is effective against neuropathic pain with few side effects. 10, 11) It was reported to be useful for the treatment of neuropathic cancer pain as an adjuvant to opioid analgesics.
12) The present results raise the possibility that gabapentin alone relieves severe cancer pain in patients.
Daily administration of gabapentin produced similar antiallodynic and antihyperalgesic effects for at least 7 d, suggesting the absence of acute tolerance. Gabapentin may be useful for long-term treatment of cancer pain.
Gabapentin may inhibit pain primarily through the action on the spinal cord.
9) It binds with a high affinity to the a 2 dsubunit of voltage-dependent Ca 2ϩ channel. 13) It suppresses evoked excitatory postsynaptic currents mediated by glutamate receptors in the spinal dorsal horn.
14) D-serine, an antagonist at the strychnine-insensitive glycine site on the NMDA glutamate receptor, inhibits antihyperalgesic effects of intrathecal gabapentin. 15) In this context, N-and P-type Ca 2ϩ channels localized at synaptic sites are involved in the release of transmitters, such as glutamate. 16) In addition, blockade of N-and P-type Ca 2ϩ channels in the spinal cord inhibits pain-related responses. 17) Thus, blockade of voltagedependent Ca 2ϩ channels may be partly involved in gabapentin analgesia. The result that ketamine, non-competitive NMDA receptor antagonist, did not produce selective antiallodynic and antihyperalgesic effects suggest that inhibition of glutamate release is not exclusively involved in gabapentin analgesia.
The aspirin-like drug diclofenac did not affect allodynia and hyperalgesia. The results support the idea that prostaglandins do not play an important role in late-phase pain in mice with melanoma inoculation.
2) The NO synthase inhibitor N G -nitro-L-arginine methyl ester inhibits inflammation-induced hyperalgesia. 18) However, it did not affect allodynia and hyperalgesia in this experiment, suggesting that NO may not be involved in this pain state. The non-specific P 2 X and P 2 Y receptor antagonist suramin (100 mg/kg) inhibits mechanical allodynia induced by nerve injury. 19) However, suramin at the same dose did not affect tactile allodynia and mechano-hyperalgesia in melanoma-bearing mice.
The Na ϩ channel blocker mexiletine, the a 2 -adrenoceptor agonist clonidine, and the GABA B receptor agonist baclofen are used for the management of cancer pain as analgesic adjuvants. 1) However, these agents did not affect tactile allodynia and mechanical hyperalgesia in melanoma-bearing mice.
In summary, although relatively high doses were needed, gabapentin markedly inhibited allodynia and hyperalgesia in a cancer pain model without apparent adverse effects. No acute tolerance was developed to the antiallodynic and antihyperalgesic effect. It may be worth testing the potency of gabapentin to inhibit cancer pains in human subjects.
